🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Another stellar Nature Medicine paper about the microbiome in RCC from a randomized prospective clinical trial from Sumanta K. Pal, MD, FASCO group with 1st authors Hedyeh Ebrahimi Nazli Dizman. Big congrats to this group !

Falls Sie es verpasst haben: Die Expertinnenliste ist da! uroforum.de/die-expertinne… #uroforum #urologie #dgu Angelika Mattigk

Day 2 of Centre of Excellence - Active discussions about the clinical cases #prostatecancer with Clàudia Mercader Antonio Alcaraz Maria J. Ribal Johnson & Johnson

Winning the Maximilian Nitze Price of the DGU #DGU24 is the most important scientific award in academic urology and urooncology in Germany. Niklas Klümper made it 🎉🍾!!! Well deserved for your hard and dedicated work for advancing medical care for urlthelial cancer

PD Dr. Niklas Klümper Niklas Klümper mit höchster wissenschaftliche Auszeichnung der DGU #DGU24 Maximilian Nitze-Preis ausgezeichnet 👏 congrats - award!

Congratulations to Gamal Wakileh for Winning the Research and Innovation Prize for Urological Oncology at #DGU24 👏🎉 DGU European Association of Urology (EAU) UroToday.com @UrooncologyUKD Uniklinik Ulm ehoonline.biomedcentral.com/articles/10.11…

Phase 1b data with the HIF2a inhibitor casdatifan in clear cell patients is out. Good response rates with a low primary progression rate. Adverse events look OK - anaemia and hypoxia. PEAK1 is a new R3 study of cabozantinib +/- casdatifan in pretreated clear cell RCC Toni Choueiri, MD

1/ JUST IN: an 8 year #kidneycancer journey now published in nature: “A personalized neoantigen vaccine generates anti-tumor immunity in high-risk renal cell carcinoma”. A trial of #RCC vaccine, led together with first author David Braun Yale Cancer Center and #PatrickOtt #DerinKeskin

TROPICS4 sacituzimab govitecan vs chemo in pretreated UC Annals of Oncology OS & PFS HRs=0.86. RR 23 vs 14, but G3+ TRAE 67 vs 35% with ⬆️ G5 TRD. While there is activity the ⬆️ tox & lower RR compared to EV/erda was problematic. Phase 2 Data on 2 other TROP2/TOPO1 ADCs #ASCOGU25

TALAPR02 looks at Talazoparib/enza vs enza in 1st line CRPC . It has significant OS in ITT HR=0.796. It’s current used in HRR deficient. Subset analysis and wider data still supports the HRR biomarker OS (HRR deficient HR -0.54, HRR non-defficent/NA 0.87), but ITT OS is +ve #GU25

NIAGRA: neoadjuvant gem/cis +/- perioperative durvalumab shows significant OS and EFS. #GU25 Matt Galsky now shows the prognostic relevance of pCR. It also showed the durvalumab outperforms the control arm irrespective of pCR. OncoAlert

Neoadjuvant disitimab Vedotin/toripalimab in 47 pts in UC. Cystectomy data on 33/47 as 14 didn’t have surgery. 21/33 surgery pts had pCR (63%) (45% of the ITT). NIAGARA had 37% in ITT, but a ⬆️% had surgery. We need a unified evaluation pCR evaluation compared to cCR etc #GU25

Extended follow up for Enfortumab/pembro in 1st line advanced UC (m 26mnths). PFS and OS HRs 0.48 & 0.51 respectively. Median duration of response is 2 yrs for the 68% who responded. The 30% with CR have75% & 95% 2 year PFS and OS respectively. Overall G3+ AEs 56 vs 57 % #GU25

From the March issue: Tracking Non-Genetic Evolution from Primary to Metastatic Clear Cell Renal Cell Carcinoma: #TRACERx Renal brnw.ch/21wRr47 By Ángel Fernández Sanromán, Annika Fendler @[email protected], Turajlic Lab @ The Crick, and colleagues The Crick CNIO Stop Cancer Charité - Universitätsmedizin Berlin

Feeling truly proud today. Just yesterday we were talking about how important it is to see ourselves reflected on stage and in the OR—and today, watching @albasierraD, who was once my resident, perform live surgery at #EAU25, is both powerful and deeply moving. Female surgeons

Micro-ultrasonography-guided biopsy is noninferior to MRI-guided fusion biopsy for the detection of clinically significant prostate cancer in biopsy naïve men. ja.ma/4hzTwTo #EAU25 Julian Struck Moises Socarras Dr. Christopher Fung Arvin K. George, MD JG Pereira

Superstar panel of mentors AND mentees at the young investigators panel this morning! #IKCSEU25

🙌 Great group to welcome us to #IKCSEU25 today!

B.C. Leibovich MD envisions the future of RCC surgery including computer vision, in vivo histology, personalized systemic therapy, anesthesiology and ambulatory care and…nanobots to replace surgeons !!! #EIKCS25 #IKCSEU25